14 December 2017 
EMA/192236/2017  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Yervoy 
ipilimumab 
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
See Annex A 
Route(s) of administration: 
See Annex A 
Packaging and package 
See Annex A 
size(s): 
Number(s)in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  Bristol-Myers Squibb Pharma EEIG 
Uxbridge Business Park 
Sanderson Road 
Uxbridge 
UB8 1DH 
UNITED KINGDOM 
Procedure  
Procedure number: 
EMEA/H/C/002213/II/0044 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and 
in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
- the development of this product has complied with all measures in the agreed paediatric 
investigation plan PIP P/0003/2017. All studies in the agreed paediatric investigation plan PIP 
P/0003/2017 were conducted after the entry into force of that Regulation, 
- the Summary of Product Characteristics reflects the results of studies conducted in compliance 
with this agreed paediatric investigation plan. 
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating 
compliance with the agreed completed paediatric investigation plan PIP P/0003/2017 is included in 
the technical dossier.  
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5555 
Send a question via our website www.ema.europa.eu/contact                                          
  An agency of the European Union    
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
